Taken together, the data indicate that overactive EGF/EGFR signaling contributes to the pathophysiology of AD and ARPKD, suggesting that inhibition of this pathway is a potential therapeutic target. The gene discussed is EGF; the disease is autosomal recessive polycystic kidney disease.